A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis

K. Jordan, A. Hinke, Axel F Grothey, W. Voigt, D. Arnold, H. H. Wolf, H. J. Schmoll

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Goals of work: Comparing antiemetic efficacy of different 5-HT 3-receptor antagonists (5-HT3RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV). Patients and methods: Comparisons between 5-HT3RAs were based on 44 randomized studies (including 12,343 patients) identified by MEDLINE, CANCERLIT or EMBASE searches and subcategorized by chemotherapy type (cisplatin- or non-cisplatin-based). Main results: When all studies were combined, granisetron was equivalent to ondansetron (n = 27), and showed an advantage vs tropisetron (p = 0.018; n = 12). Ondansetron vs tropisetron (n = 11) and ondansetron vs dolasetron (n = 3) revealed equivalence in each comparison. An advantage for 3 mg granisetron vs 8 mg ondansetron was found in non-cisplatin-based studies (p = 0.015; n = 6). Overall equivalence was seen between ondansetron, 24 or 32 mg, and granisetron, 2 or 3 mg, for all studies (n = 13). There was a possible advantage for higher (24 or 32 mg) vs lower (8 mg) ondansetron dose regimens with cisplatin-based trials (n = 6). No differences were seen between 3 and 1 mg granisetron doses (n = 6). Conclusions: Efficacy of 5-HT3RAs for preventing CINV following cisplatin- and non-cisplatin-based chemotherapy is comparable, with the exception of granisetron vs tropisetron. Some differences were noted in dosing subanalyses.

Original languageEnglish (US)
Pages (from-to)1023-1033
Number of pages11
JournalSupportive Care in Cancer
Volume15
Issue number9
DOIs
StatePublished - Sep 2007

Fingerprint

tropisetron
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Ondansetron
Granisetron
Vomiting
Meta-Analysis
Drug Therapy
Serotonin Receptors
Cisplatin
Nausea
Antiemetics
MEDLINE

Keywords

  • 5-HTRAs
  • Antiemetic
  • Chemotherapy
  • Dosing regimens
  • Efficacy

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Jordan, K., Hinke, A., Grothey, A. F., Voigt, W., Arnold, D., Wolf, H. H., & Schmoll, H. J. (2007). A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Supportive Care in Cancer, 15(9), 1023-1033. https://doi.org/10.1007/s00520-006-0186-7

A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. / Jordan, K.; Hinke, A.; Grothey, Axel F; Voigt, W.; Arnold, D.; Wolf, H. H.; Schmoll, H. J.

In: Supportive Care in Cancer, Vol. 15, No. 9, 09.2007, p. 1023-1033.

Research output: Contribution to journalArticle

Jordan, K, Hinke, A, Grothey, AF, Voigt, W, Arnold, D, Wolf, HH & Schmoll, HJ 2007, 'A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis', Supportive Care in Cancer, vol. 15, no. 9, pp. 1023-1033. https://doi.org/10.1007/s00520-006-0186-7
Jordan, K. ; Hinke, A. ; Grothey, Axel F ; Voigt, W. ; Arnold, D. ; Wolf, H. H. ; Schmoll, H. J. / A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. In: Supportive Care in Cancer. 2007 ; Vol. 15, No. 9. pp. 1023-1033.
@article{aa7a55c5c1c64c6cafb56d72663b1463,
title = "A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis",
abstract = "Goals of work: Comparing antiemetic efficacy of different 5-HT 3-receptor antagonists (5-HT3RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV). Patients and methods: Comparisons between 5-HT3RAs were based on 44 randomized studies (including 12,343 patients) identified by MEDLINE, CANCERLIT or EMBASE searches and subcategorized by chemotherapy type (cisplatin- or non-cisplatin-based). Main results: When all studies were combined, granisetron was equivalent to ondansetron (n = 27), and showed an advantage vs tropisetron (p = 0.018; n = 12). Ondansetron vs tropisetron (n = 11) and ondansetron vs dolasetron (n = 3) revealed equivalence in each comparison. An advantage for 3 mg granisetron vs 8 mg ondansetron was found in non-cisplatin-based studies (p = 0.015; n = 6). Overall equivalence was seen between ondansetron, 24 or 32 mg, and granisetron, 2 or 3 mg, for all studies (n = 13). There was a possible advantage for higher (24 or 32 mg) vs lower (8 mg) ondansetron dose regimens with cisplatin-based trials (n = 6). No differences were seen between 3 and 1 mg granisetron doses (n = 6). Conclusions: Efficacy of 5-HT3RAs for preventing CINV following cisplatin- and non-cisplatin-based chemotherapy is comparable, with the exception of granisetron vs tropisetron. Some differences were noted in dosing subanalyses.",
keywords = "5-HTRAs, Antiemetic, Chemotherapy, Dosing regimens, Efficacy",
author = "K. Jordan and A. Hinke and Grothey, {Axel F} and W. Voigt and D. Arnold and Wolf, {H. H.} and Schmoll, {H. J.}",
year = "2007",
month = "9",
doi = "10.1007/s00520-006-0186-7",
language = "English (US)",
volume = "15",
pages = "1023--1033",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis

AU - Jordan, K.

AU - Hinke, A.

AU - Grothey, Axel F

AU - Voigt, W.

AU - Arnold, D.

AU - Wolf, H. H.

AU - Schmoll, H. J.

PY - 2007/9

Y1 - 2007/9

N2 - Goals of work: Comparing antiemetic efficacy of different 5-HT 3-receptor antagonists (5-HT3RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV). Patients and methods: Comparisons between 5-HT3RAs were based on 44 randomized studies (including 12,343 patients) identified by MEDLINE, CANCERLIT or EMBASE searches and subcategorized by chemotherapy type (cisplatin- or non-cisplatin-based). Main results: When all studies were combined, granisetron was equivalent to ondansetron (n = 27), and showed an advantage vs tropisetron (p = 0.018; n = 12). Ondansetron vs tropisetron (n = 11) and ondansetron vs dolasetron (n = 3) revealed equivalence in each comparison. An advantage for 3 mg granisetron vs 8 mg ondansetron was found in non-cisplatin-based studies (p = 0.015; n = 6). Overall equivalence was seen between ondansetron, 24 or 32 mg, and granisetron, 2 or 3 mg, for all studies (n = 13). There was a possible advantage for higher (24 or 32 mg) vs lower (8 mg) ondansetron dose regimens with cisplatin-based trials (n = 6). No differences were seen between 3 and 1 mg granisetron doses (n = 6). Conclusions: Efficacy of 5-HT3RAs for preventing CINV following cisplatin- and non-cisplatin-based chemotherapy is comparable, with the exception of granisetron vs tropisetron. Some differences were noted in dosing subanalyses.

AB - Goals of work: Comparing antiemetic efficacy of different 5-HT 3-receptor antagonists (5-HT3RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV). Patients and methods: Comparisons between 5-HT3RAs were based on 44 randomized studies (including 12,343 patients) identified by MEDLINE, CANCERLIT or EMBASE searches and subcategorized by chemotherapy type (cisplatin- or non-cisplatin-based). Main results: When all studies were combined, granisetron was equivalent to ondansetron (n = 27), and showed an advantage vs tropisetron (p = 0.018; n = 12). Ondansetron vs tropisetron (n = 11) and ondansetron vs dolasetron (n = 3) revealed equivalence in each comparison. An advantage for 3 mg granisetron vs 8 mg ondansetron was found in non-cisplatin-based studies (p = 0.015; n = 6). Overall equivalence was seen between ondansetron, 24 or 32 mg, and granisetron, 2 or 3 mg, for all studies (n = 13). There was a possible advantage for higher (24 or 32 mg) vs lower (8 mg) ondansetron dose regimens with cisplatin-based trials (n = 6). No differences were seen between 3 and 1 mg granisetron doses (n = 6). Conclusions: Efficacy of 5-HT3RAs for preventing CINV following cisplatin- and non-cisplatin-based chemotherapy is comparable, with the exception of granisetron vs tropisetron. Some differences were noted in dosing subanalyses.

KW - 5-HTRAs

KW - Antiemetic

KW - Chemotherapy

KW - Dosing regimens

KW - Efficacy

UR - http://www.scopus.com/inward/record.url?scp=34548349175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548349175&partnerID=8YFLogxK

U2 - 10.1007/s00520-006-0186-7

DO - 10.1007/s00520-006-0186-7

M3 - Article

C2 - 17205281

AN - SCOPUS:34548349175

VL - 15

SP - 1023

EP - 1033

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 9

ER -